Skip to main content
. Author manuscript; available in PMC: 2023 Jun 22.
Published in final edited form as: Nat Med. 2023 Jan 31;29(3):623–631. doi: 10.1038/s41591-023-02241-7

Table 3 |.

Determinants of early, late and nonvaccination status among older adults

Multinomial logit regressiona (1) Phase 1 vaccination (Jan 2021-Jul/Aug 2021) versus nonvaccination (2) Phase 2 vaccination (Jul/Aug 2021-Jul/Aug 2022) versus nonvaccination (3) Phase 2 versus phase 1 vaccination
n=9,890 n=9,890 n=9,890
RRR (95% CI) P RRR (95% CI) P RRR (95% CI) P
Female 0.80 (0.67–0.95) 0.010 0.82 (0.68–0.99) 0.035 1.03 (0.93–1.13) 0.605
Married 1.65 (1.35–2.01) 0.000 1.38 (1.12–1.71) 0.003 0.84 (0.72–0.97) 0.020
Minority ethnicity 0.58 (0.40–0.84) 0.004 1.38 (0.97–1.96) 0.075 2.39 (1.92–2.97) 0.000
Urban residence 0.59 (0.47–0.73) 0.000 0.41 (0.32–0.52) 0.000 0.70 (0.59–0.84) 0.000
Age group (reference: 52–59)
 60–69 0.93 (0.73–1.18) 0.530 2.03 (1.54–2.69) 0.000 2.20 (1.85–2.61) 0.000
 70–79 0.66 (0.51–0.85) 0.001 2.21 (1.66–2.95) 0.000 3.35 (2.78–4.03) 0.000
 80+ 0.19 (0.14–0.26) 0.000 1.63 (1.18–2.25) 0.003 8.44 (6.65–10.72) 0.000
Education (reference: illiterate)
 Primary school (literate) 1.00 (0.82–1.23) 0.969 0.99 (0.80–1.22) 0.900 0.98 (0.86–1.12) 0.792
 Middle, high school and higher 1.12 (0.87–1.44) 0.388 0.87 (0.66–1.14) 0.311 0.78 (0.66–0.92) 0.003
Region (reference: East)
 Central 0.88 (0.71–1.09) 0.231 0.97 (0.77–1.22) 0.802 1.11 (0.95–1.29) 0.207
 West 1.38 (1.10–1.74) 0.006 1.59 (1.25–2.02) 0.000 1.15 (0.99–1.35) 0.070
 Northeast 1.06 (0.75–1.49) 0.742 2.03 (1.41–2.92) 0.000 1.91 (1.51–2.43) 0.000
 Functionally dependent 0.20 (0.17–0.24) 0.000 0.48 (0.40–0.59) 0.000 2.41 (2.08–2.79) 0.000
Chronic conditions
 Hypertension 0.78 (0.66–0.92) 0.004 1.01 (0.85–1.21) 0.874 1.30 (1.16–1.45) 0.000
 Heart disease 0.57 (0.47–0.70) 0.000 0.65 (0.53–0.80) 0.000 1.14 (0.99–1.31) 0.064
 Stroke 0.59 (0.45–0.77) 0.000 0.91 (0.69–1.19) 0.475 1.53 (1.25–1.87) 0.000
 Diabetes 0.74 (0.59–0.92) 0.008 0.90 (0.71–1.13) 0.372 1.21 (1.04–1.42) 0.014
 Lung disease 0.73 (0.58–0.92) 0.007 0.73 (0.58–0.93) 0.012 1.00 (0.85–1.18) 0.982
 Cancer 0.20 (0.14–0.28) 0.000 0.44 (0.31–0.63) 0.000 2.20 (1.60–3.03) 0.000
 Dysli pidemia 1.25 (1.02–1.52) 0.029 1.12 (0.90–1.38) 0.316 0.89 (0.78–1.03) 0.111
 Liver disease 0.91 (0.65–1.28) 0.585 0.93 (0.65–1.33) 0.681 1.02 (0.81–1.28) 0.867
 Kidney disease 0.72 (0.55–0.94) 0.018 0.71 (0.53–0.95) 0.021 0.99 (0.81–1.20) 0.910
 Asthma 0.90 (0.65–1.24) 0.513 1.00 (0.72–1.39) 0.997 1.11 (0.88–1.42) 0.381
 Arthritis/rheumatism 1.54 (1.29–1.86) 0.000 1.23 (1.01–1.49) 0.038 0.79 (0.71–0.89) 0.000
 Digestive disease 1.22 (1.01–1.47) 0.042 1.05 (0.85–1.29) 0.651 0.86 (0.76–0.97) 0.018
a

The dependent variable has three discrete outcomes, each compared to the one used as the baseline outcome. All results are from one multinomial logit regression and each column shows the results from an outcome pair. In column 3, only the baseline outcome changed, so the RRRs are the quotients between those from columns 2 and 1. Standard errors are clustered at the household level. The phase 1 vaccination campaign ran from January 2021 to July/August 2021 and represents the early period when vaccines had not been available for more than 6 months; the phase 2 vaccination campaign ran from July/August 2021 to July/August 2022 and represents the later period. The 95% CI was calculated based on a Wald test.